Novo Nordisk A/S has been cleared to pursue legal action against a compound pharmacy for false advertising related to its weight-loss products, adding to the company's current legal challenges. Despite this turbulence, the pharmaceutical giant's shares have climbed 14.5% since the beginning of the year, driven by the successful launch of its Wegovy pill and positive revenue growth forecasts of 8% to 11%. In a bid to streamline operations, Novo has announced significant job cuts of 9,000 positions, reflecting the competitive landscape in the weight-loss drug market.
“Novo Nordisk A/S can move forward with a lawsuit against a compound pharmacy that allegedly falsely advertised its weight-loss products as equivalent to generic versions of Ozempic, Wegovy, and Rybelsus, a federal judge said.”
“Novo Nordisk A/S can move forward with a lawsuit against a compound pharmacy that allegedly falsely advertised its weight-loss products as equivalent to generic versions of Ozempic, Wegovy, and Rybelsus, a federal judge said.”
“Lilly · has been racing against · Danish rival Novo Nordisk · to meet surging demand for GLP-1 weight-loss drugs”
“Novo Nordisk · is up · percentage since start of year · 14.5%”
“Novo Nordisk · expected to have risen · full-year revenue · 8% to 11%”
“Novo Nordisk · shares are up · since the start of the year · 14.5%”
“Novo Nordisk · said it would cut · jobs · 9,000”
“Novo Nordisk · shares are up · 14.5% · since the start of year”
“Novo Nordisk · expects · full-year revenue growth · 8% to 11%”
“Novo Nordisk · launched · Wegovy weight-loss pill · in the US”
“Novo Nordisk's full-year revenue · is now expected to have risen · percentage range · 8% to 11%”
“Novo Nordisk · is up · percentage · 14.5%”
